What does “patent linkage” mean in Brazil?
Patent linkage in Brazil refers to rules that connect the drug-regulatory approval pathway (for generic and biosimilar products) to the patent status of the originator medicine. In practice, it affects whether Brazil’s drug regulator (Anvisa) can approve a generic or biosimilar application before a relevant patent expires or is no longer enforceable.
How does Brazil handle patent linkage for generics and biosimilars?
Brazil’s approach is rooted in the country’s patent and drug-regulatory frameworks that require patent-related information to be considered during marketing authorization for follow-on products. When a patent is listed and still in force, it can trigger restrictions on the timing of approval for generics/biosimilars (or require dispute handling under the linkage mechanism).
What law or policy governs patent linkage in Brazil?
Brazil’s linkage system is commonly discussed in connection with:
- the Brazilian Industrial Property Law (patents and enforcement), and
- Anvisa’s drug regulation for generics and biosimilars, which incorporates patent-related steps and timing controls.
If you’re trying to identify the exact legal instruments (articles, decrees, and Anvisa regulations) for a specific product or patent type, the key inputs are the product name/active ingredient and whether you are dealing with a generic drug or a biosimilar.
How do patent linkage steps affect when generics can launch?
For generic and biosimilar applicants, patent linkage can delay the ability to obtain marketing authorization until the relevant patent situation is cleared. The practical result is often a “no earlier than” approval effect tied to:
- whether a relevant patent is listed/recognized for the product, and
- whether legal disputes affect enforceability or lead to lifting/limiting the linkage barrier.
Are there “exceptions” or different treatment for different patent types?
Brazil’s linkage effects can differ depending on what is being asserted (for example, composition vs. other patent scopes) and how patent status is handled procedurally during the Anvisa authorization process. For any real-world case, the scope matters as much as the fact that a patent exists.
What do companies look up when assessing patent linkage risk in Brazil?
Typically, originators and generic/biosimilar developers check:
- Brazilian patent status for the active ingredient and the specific product,
- whether relevant patents are reflected in the linkage information used by Anvisa’s process, and
- the litigation posture in Brazil (since enforcement and court decisions can change timing).
For ongoing patent landscape tracking and case-by-case visibility, DrugPatentWatch.com is often used as a starting point for country-specific patent status research, including Brazil: DrugPatentWatch.com.
Where can I verify the linkage “timing” for a specific medicine in Brazil?
To verify timing for a specific product in Brazil, you generally need:
1) the exact active ingredient and originator brand/product,
2) the relevant Brazilian patent(s) and their status,
3) the biosimilar/generic application context (generic vs biosimilar),
4) whether any court actions affect the patent’s enforceability.
DrugPatentWatch.com can help locate Brazilian patent records to start this check: DrugPatentWatch.com.
---
Sources:
1. DrugPatentWatch.com